<DOC>
	<DOCNO>NCT00681863</DOCNO>
	<brief_summary>The primary objective open-label , flexible dose study assess safety efficacy pramipexole 24-week period child adolescent ( age 6-17 year inclusive ) diagnose Tourette Syndrome accord Diagnostic Statistical Manual Mental Disorders , 4th Edition ( DSM-IV ) criterion complete either Study 248.641 ( NCT 00681863 ) 248.644 ( NCT 00558467 ) .</brief_summary>
	<brief_title>Open-label Extension Study Pramipexole Treatment Children Adolescents With Tourette Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Tourette Syndrome</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Inclusion criterion 1 . Male female patient age 617 year time enrollment study 248.641 248.644 complete study 248.641 248.644 . 2 . Written inform consent provide patient 's parent ( legal guardian ) assent provide patient consistent International Conference Harmonization ( ICH ) Good Clinical Practice ( GCP ) local Institutional Review Board ( IRB ) requirement child obtain prior study procedure perform . 3 . Ability willingness comply study treatment regimen complete study assessment . 4 . Females childbearing potential negative serum pregnancy test Visit 1 . 5 . Females childbearing potential must use medically accept contraceptive method throughout study . Acceptable method birth control limit : IntraUterine Device ( IUD ) , oral , implantable , injectable contraceptive estrogen patch , double barrier method ( spermicide + diaphragm ) , abstinence discretion investigator Exclusion criteria 1 . Breastfeeding female . 2 . Development clinical condition precede trial investigator 's opinion could worsen treatment pramipexole . 3 . Clinically significant renal disease serum creatinine range : 0.3 1.0 mg/dL patient age 312 year 0.51.4 mg/dL patient age 13+ year . 4 . Any following lab result screen : Hemoglobin ( Hgb ) low limit normal ( LLN ) determine clinically significant Basal thyroid stimulate hormone ( TSH ) , triiodothyronine ( T3 ) thyroxine ( T4 ) clinically significant ( investigator 's discretion ) normal range screening ( cause substitution therapy accord investigator 's opinion ) Patients clinically significant abnormality laboratory parameter screen investigator 's discretion . 5 . Other clinically significant metabolicendocrine , hematological , gastrointestinal disease , pulmonary disease ( severe asthma ) opinion investigator would preclude patient participate study . 6 . History presence schizophrenia psychotic disorder . History presence psychiatric disorder require medical therapy exception patient diagnosis Tourette Syndrome ( TS ) , Attention Deficit Hyperactivity Disorder ( ADHD ) Obsessive Compulsive Disorder ( OCD ) therapy pramipexole . 7 . History presence clinical sign epilepsy seizure feverrelated seizure early childhood . 8 . History presence clinical sign malignant neoplasm include suspicious undiagnosed skin lesion ( may melanoma ) , melanoma , history melanoma . 9 . History medical treatment TS besides study medication within 28 day prior baseline visit ( 14 day prior baseline guanfacine , 14 day prior baseline dopamine agonist , 14 day prior baseline LDopa , 35 day prior baseline fluoxetine ) . 10 . Patients receive psychotherapy exclude unless start treatment least 3 month prior start trial change treatment plan duration study . 11 . Allergic response pramipexole inactive ingredient tablet formulation . 12 . Noncompliance study medication ( define less 80 % 120 % ) preceding Study 248.641 248.644 . 13 . Concurrent participation another clinical trial use investigational drug since completion precede Study 248.641 248.644 . 14 . Any condition , opinion investigator , would interfere evaluation result constitute health hazard patient .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>